- Appointment brings significant investment banking and cross border transaction experience -
Munich, Germany, and London, UK, 27 September 2006 - Trigen, the cardiovascular drug discovery and development company, today announced the appointment of Grahame Cook as a non-executive member of its Supervisory Board with effect from 30 August 2006. He will also establish and chair Trigen's Audit Committee.
Dr Goran Ando, non-executive Chairman of Trigen's Supervisory Board commented, "We are delighted to welcome Grahame to the Trigen Supervisory Board. He has a range of skills and experience, particularly in finance and M&A, that complement ideally the competences within the Board."
Commenting on his appointment Grahame Cook said "Trigen is a very impressive company. It has a clear focus on a significant area of medical need combined with a competitive clinical-stage product pipeline, portfolio of novel discovery-stage programs and clear corporate strategy. Taken together these attributes position the company well for the future. I look forward to working closely with the Supervisory and Management Boards as Trigen progresses."
Until 2003, Grahame was the CEO of West LB Panmure, West LB's investment banking business, where he was responsible for the expansion and development of the bank's business, achieving a substantial increase in market share. At the same time, he established West LB's Pan-European Life Sciences Team, now Nomura Code, which was number one in the industry in terms of money raised for clients in 1998-2000.
Grahame previously held a number of senior investment banking positions at UBS between 1995 and 1998, where he was a member of the Global Management Committee and Global Head of Industry Sectors and where he was responsible for initiating a number of cross-border merger and buyout transactions. Grahame initially trained as a chartered accountant with accountancy firm Arthur Anderson & Co.
Grahame currently holds a number of non-executive positions at biopharmaceutical companies such as Antisoma plc, Sinclair Pharma and Morphogenesis Inc and the US/European investment bank, Moore Clayton & Co.
Dr Sanjay Kakkar, Trigen's CEO added, "We are privileged to attract someone of Grahame's calibre to our Board. I am confident that his tremendous city background and experience will be an asset to Trigen and its shareholders."
Trigen is a biopharmaceutical company, with operations in London and Munich and a leader in cardiovascular drug discovery and development, focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical-stage candidates TGN 255, TGN 167 and PR-15. The company also has an extensive portfolio of exciting pre-clinical and discovery stage programmes targeting thrombosis, atherosclerosis and other cardiovascular pathologies. In addition, Trigen benefits from two established discovery platforms, SIGSCREEN® and THROMSCAN® which have been applied in collaborations with a number of multinational pharmaceutical companies. For further information on Trigen please refer to the company website at http://www.trigen.co.uk or http://www.trigen.de
Ashley Tapp Head of Corporate Communications Trigen Tel: +44 (0)20 7004 2653 Mob: +44 (0)7944 570387 Email: firstname.lastname@example.org
Mary Clark/Shaun Brown Capital MS&L Tel: +44 (0)20 7307 5336/5337 Email: email@example.com firstname.lastname@example.org